Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2002-07-19
2008-08-12
Salimi, Ali R. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S069100
Reexamination Certificate
active
07410758
ABSTRACT:
The present invention concerns the use of E6 and/or E7 peptides from human papilloma virus (HPV) to evaluate a cell-mediated response in a patient infected with HPV to determine the prognosis for that patient with respect to the development or recurrence of pre-cancerous or cancerous growths, including cervical intraepithelial neoplasia (CIN).
REFERENCES:
patent: 5665535 (1997-09-01), Orth et al.
patent: 5876922 (1999-03-01), Orth et al.
patent: 6135965 (2000-10-01), Tumer et al.
patent: 6258576 (2001-07-01), Richards-Kortum et al.
patent: 0 402 132 (1990-06-01), None
patent: 0 520 994 (1995-01-01), None
Baay et al., “Humoral immune response against proteins E6 and E7 in cervical carcinoma patients postive for human papilloma virus type 16 during treatment and follow-up,”Eur. J. Clin. Microbiol. Infect. Dis., 18:126-132, 1999.
Bonagura et al., “Recurrent respiratory papilomatosis: Altered CD8+ T-cell subsets and TH1/TH2 cytokine imbalance,”Clin. Immunol., 93:302-311, 1999.
De Silva et al., “Cervical cancer vaccines: emerging concepts and developments,”J. Cellular Physiol., 186:169-182, 2001.
Sarkar et al., “Association of significant cellular immune responses to synthetic peptides from E6 and E7 oncoproteins of HPV-16 with disease-free condition in HPV+ patients treated for cervical intrapithelial nesplasia,”J. Acquired Immune Deficiency Syndromes Human Retrovirology, 17:A29, 1998.
Stellato et al., “Type 1 cytokine response and treatment outcome of genital HPV lesions,”Genitourinary Med., 73:387-390, 1997.
Viladiu et al., “Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2, and E7 peptides as predictors of survival in patients with squamous cell cervical cancer,”J. Clin. Oncology, 15:610-619, 1997.
Aichele et al., “Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide,”J. Exp. Med., 171(5):1815-1820, 1990.
Borysiewicz et al., “A recombinant vaccina virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer,”Lancet, 347:1523-1527, 1996.
Casement et al., “Cross-reactive cytotoxic T lymphocytes induced by V3 loop synthetic peptides from different strains of human immunodeficiency virus type 1,”Virology, 211(1):261-267, 1995.
Cason et al., “Detection of anitbodies to a linear epitope on the major coat protein (L1) of human papillomavirus type-16 (HPV-16) in sera from patients with cervical intraepithelial neoplasia and children,”Int. J. Cancer, 50:349-355, 1992.
Chen et al., “Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16,”J Immunol., 148(8):2617-2621, 1992.
Clavel et al., “Human papillovirus detection by the hybrid capture II assay: a reliable test to select women with normal cervical smears at risk for developing cervical lesions,”Diagn. Mol. Pathol., 9(3):145-150, 2000.
Clerici et al., “Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection,”J. Natl. Cancer Inst., 89(3):245-250, 1997.
de Gruijil et al., “T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection ,”J Gen Virol., ( Pt 9):2183-91. 1996.
Deres et al., “In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine,”Nature, 342(6249):561-564, 1989.
Dillner et al., “Mapping of linear epitopes of human papillomavirus type 16 the L1 and L2 open reading framed,”Int. J. Cancer, 45:529-535, 1990.
Feltkamp et al., “Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a turmor induced by human papillomavirus type 16-transformed cells,”Eur. J. Immunol., 23:2242-2249, 1993.
Fischer et al., “The association of human papillomavirus type 16 E6 and E7 antibodies with stage of cervical cancer,”Gynecologic Oncology, 61, No. 0099, 73-78, 1996.
Hamsikova et al., “Presence of antibodes to seven human papillomavirus type 16-derived peptides in cervical cancer patients and healthy controls,”J. Infect. Dis., 170:1424-1431, 1994.
Jha et al., “Antibodies to human papillomavirus and to other genital infectious agents and invasive cervical cancer risk,”Lancet, 341:1116-1118, 1993.
Kadish et al., “Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia,”J. Natl. Cancer Inst., 89:1285-1293, 1997.
Kast et al., “In vivo efficacy of virus-derived peptides and virus-specific cytotoxic T lymphocytes,”Immunol Lett., 30(2):229-232, 1991.
Kast et al., “Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2,”J. Immunotherapy, 14:115-120, 1993.
Lorenzato et al., “DNA image cytometry and human papillomavirus (HPV) detection help to select smears at high risk of high-grade cervical lesions,”J. Pathol., 194(2):171-176, 2001.
Müller et al., “Identification of seroreactive regions of the human papillomavirus type 16 proteins E4, E6, E7 and L1,”Journal of General Virology, 71:2709-2717, 1990.
Munger et al., “The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes,”J. Virol., 63:4417-4421, 1989.
Nakagawa et al., “T-cell proliferative responses to human papillomavirus type 16 peptides: relationship to cervical intraepithelial neoplasia,”Clin. Diag. Lab. Immunol., 3(2):205-210, 1996.
Nakagawa et al., “Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia,”J. Infect. Dis., 175:927-931, 1997.
Nehete et al., “Cross-reactive T-cell proliferative responses to V3 peptides corresponding to different geographical HIV-1 isolates in HIV-seropositive individuals,”J. Clin. Immunol., 16(2):115-124, 1996.
Nindl et al., “Antibodies against linear and conformational epitopes of the human papillomavirus (HPV) type 16 E6 and E7 oncoproteins in sera of cervical cancer patients,”Archives of Virology, 137:341-353, 1994.
Park et al., “Cell-mediated immunity in cervical intraepithelial neoplasia,”Asia-Oceania J. Obstet. Gynaecol., 18:171-175, 1992.
Poljak et al., “Comparative evaluation of first- and second-generation digene hybrid capture assays for detection of human papillomaviruses associated with high or intermediate risk for cervical cancer,”J. Clin. Microbiol., 37(3):796-797, 1999.
Ressing et al., “Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicigy studies of HLA-A 0201-binding peptides,”J. Immunology, 154:5934-5943, 1995.
Ressing et al., “Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A 0201-restricted E7-encoded epitome,”Cancer Res., 56:582-588, 1996.
Rochlitz et al., “Mutations in the ras protooncogenes are rare events in renal cell cancer,”Eur. J. Cancer, 28(2/3):333-336, 1992.
Sasagawa et al., “Identification of antibodies against human papillomavirus type 16 E6 and E7 proteins in sera of patients with cervical neoplasias,”Japanese Journal of Cancer Research, 83:705-713, 1992.
Sarkar et al., “Studies on in vivo induction of cytotoxic T lymphocyte responses by synthetic peptides from E6 and E7 oncoproteins of human papillomavirus type 16,”Viral Immunol., 8(3):165
Follen Michele
Sastry Jagannadha K.
Tortolero-Luna Guillermo
Board of Regents the University of Texas System
Fulbright & Jaworski L.L.P.
Salimi Ali R.
LandOfFree
Methods and compositions relating to HPV-associated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions relating to HPV-associated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions relating to HPV-associated... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4009353